American Oncology Network, Inc.

Moat Score
Safety Score

Market Cap $141.92K
PE -0
Debt $95.25M
Cash $19.43M
EV $75.96M
FCF -$46.21M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$51.72M
EBIT	-$46.26M
ROE	-80%
ROA	-12%
FCF	-$46.21M
Equity	$65.00M
Growth Stability	1
PE	-0
PB	0
P/FCF	-0
P/S	0
Price/Cash	136.92
Debt/Equity	1.47
Debt/FCF	-2.06
Net Margins	-2%
Gross Margins	5%
Op. Margins	-3%
Sales Growth YoY	40%
Sales Growth QoQ	8%
Sales CAGR	5%
Equity CAGR	53%
Earnings Growth YoY	-97%

Earnings Growth QoQ	-59%
Sales CAGR 5Y	5%
Equity CAGR 5Y	53%
Earnings CAGR 3Y	13%
Sales CAGR 3Y	13%
Equity CAGR 3Y	5%
Market Cap	$141.92K
Revenue	$1.59B
Assets	$394.81M
Total Debt	$95.25M
Cash	$19.43M
Shares Outstanding	32.63K
EV	75.96M
Moat Score	9%
Safety Score	62%
Working Capital	71.37M
Current Ratio	1.36
Gross Profit	$83.94M
Shares Growth 3y	-11%
Equity Growth QoQ	0%
Equity Growth YoY	0%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Digital Transformation Opportunities Corp. is a blank check company. The Company is created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Company focuses on the healthcare industry, with a particular focus on healthcare technology and adjacent verticals. It has no operations and has no revenues.

SEC Filings

Direct access to American Oncology Network, Inc. (AONC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does American Oncology Network, Inc. compare to its competitors?

Not enough data to generate a comparison chart between American Oncology Network, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of American Oncology Network, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

American Oncology Network, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for American Oncology Network, Inc..

Years

Calculation mode

= -$462M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$46M	-$46M	-$46M	-$46M	-$46M	-$46M	-$46M	-$46M	-$46M	-$46M	-$46M	-$462M
DCF		-$42M	-$38M	-$35M	-$32M	-$29M	-$26M	-$24M	-$22M	-$20M	-$18M	-$178M
Value	-$462M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-0%	0%	0%	-5%	-2%
ROA	-	3%	3%	-13%	-12%
ROE	-	0%	0%	-97%	-80%

Bad Net Margins (-2.31%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-6.8	-10.17	-2.67	-2.06
Debt over Equity	-	1.09	1.31	1.25	1.47
Growth Stability	-	-	-	-	1

Good Debt/FCF ratio (-2.06)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Neutral Debt/Equity ratio (1.47)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	30%	22%	11%	5%
Earnings YoY growth	-	-100%	-	-	-
Equity YoY growth	-	-0%	4%	5%	53%
FCF YoY growth	-	-138%	-16%	281%	-